Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

CoreAge Rx vs Good Girl Rx

By GLP-1 ScorecardUpdated

CoreAge Rx
Site position #1

Higher grade

Good Girl Rx
Site position #455

Lower grade

Score comparison

CoreAge Rx has the higher recorded score — 89.5/100 to 56.9/100.

CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

CoreAge Rx scores 89.5/100 (B+).

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueCoreAge Rx +64
92
28
Dose & formulationEven
88
88
Clinical oversightCoreAge Rx +38
93
55
Labs & monitoringCoreAge Rx +38
90
52
FulfillmentCoreAge Rx +10
95
85
Contract termsCoreAge Rx +26
67
41
CoreAge Rx · top barGood Girl Rx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricCoreAge RxGood Girl Rx
WeighScore89.5/10056.9/100
GradeB+C
Site position#1#455
SemaglutideProduct page from $79/mo; navigation $99. Confirm selected quote.$79/mo (microdose tier, 12-month plan, compounded)
TirzepatideFrom $129/mo advertised; confirm selected charge, supply and renewal.$139/mo (microdose tier, 12-month plan, compounded)
CoverageUS only; therapy-specific state restrictions applyAll 50 states
Brand-name accessNot confirmedYes
Oral / sublingualNot confirmedYes
CoreAge Rx

Site position #1 · B+

Strengths

  • Current product pages advertise starting prices of $79 for semaglutide and $129 for tirzepatide
  • Advertises the same price across doses and no membership fee
  • Publishes cancellation, fulfillment and refund rules and a way to request the assigned pharmacy

What to consider

  • Starting prices vary across public displays and do not establish a selected invoice or usable prescription supply
  • FAQ no-rebill and payment-timing statements differ from the subscription and order policy
  • FAQ promises a full rejection refund, while policy retains an applicable $50–$100 consultation fee after review begins
  • Refund policy makes orders final after approval and pharmacy transmission; Terms also refer to review completion/transmission with policy exceptions. Confirm the cutoff and separate thirty-day documentation limit.
  • Actual clinician, dispenser, physical compounder, lab cost and treatment-state eligibility need confirmation
Good Girl Rx

Site position #455 · C

FDAWarning letter issued to Good Girl LLC dba GoodGirlRX in February 2026. See the FDA warning-letter database.

Strengths

  • LegitScript certified
  • Multiple formats — injectable, microdose, and ODT pills — for both semaglutide and tirzepatide
  • Dispensed by licensed 503A or 503B pharmacies
  • Limited brand-name options available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • Named legal entity with a Nashville address

What to consider

  • The advertised rates require twelve months paid up front; billed month to month the same products are $184 and $244, roughly 2.3 times as much
  • Every plan is prepaid — the discount exists only on the 3-, 6- and 12-month terms
  • The priced products are microdoses, not labeled therapeutic doses; the standard compounded semaglutide is $134/mo and also needs a year up front
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
  • FDA issued Good Girl LLC dba GoodGirlRX a warning letter in February 2026; the letter is public in FDA's warning-letter database

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard